Takeda Healthcare Philippines receives double recognition at the Asia Responsible Enterprise Awards

Tweet

Takeda Philippines Healthcare, Inc. (“Takeda”), a leading pharmaceutical company committed to create better health for people and a brighter future for the world, has been recognized with two prestigious awards at the Asia Responsible Enterprise Awards (AREA) ceremony held in Cambodia.

 Takeda Philippines Country Leadership Team (Seated from L to R) Sheryll Anne Corpuz, Estela del Rosario, Loreann Villanueva, Arabella Benito, Armi Grace Gonzales

(Standing From L to R) John Raymond Gulinao, Fatima Mangalindan, Rommel Velasco, Joy Althea Pabellon, Freddie Deinla

The first award was given to Takeda's Access To Medicines: Patient Assistance Program (AtM Program) in the Health Promotion category. Rooted in the vision of broadening access to life-changing medicines and vaccines in underserved communities, the AtM Program utilizes an integrated and sustainable approach that mobilizes the collective efforts of all involved stakeholders.

Focusing on diseases with the highest unmet need such as cancer and rare diseases, Takeda strives to bring its innovative and high-quality medicines to patients in the Philippines who have limited access to healthcare services. Through this program, the company has successfully provided financial assistance to over 600 patients nationwide, ensuring they receive crucial treatments regardless of their capacity to pay.

The AtM Program involves multi-stakeholder collaboration to address the pain points in the patient’s journey in the areas of disease awareness, accurate diagnosis, and appropriate treatment, support, and care. Based on Takeda’s insights on Filipino patients, it takes them about 5 to 10 visits to different doctors before they are properly diagnosed. Thus, the “Spot Lymphoma, Stop Lymphoma” campaign was launched together with 5 major medical societies and 2 non-government organizations to educate patients. Takeda in partnership with Philippine Cancer Society (PCS) provided CD30 screening through 24 hospitals majority of which are located outside of the capital of Metro Manila so patients would have access to CD30 screening.

Aside from screening, a series of workshops with Philippine Pathologists in partnership with medical societies were done to increase the skills and confidence of pathologists in utilizing immunohistochemistry and ensure early and proper diagnosis. The cornerstone of Takeda’s access program in the country is the Patient Assistance Program (PAP). This unique and innovative affordability-based program enabled more than 600 patients regardless of their socio-economic class to access their treatment with Takeda’s target therapy at a price that is based on the patient’s financial capacity to pay.

Takeda also partnered with an NGO to provide a series of training to oncology nurses to enrich their capability in educating patients. They also provided a grant to the Cancer Care Registry and Research Philippines Foundation (CARE PH) to expand its cancer registry and research.

Finally, as a culmination of Takeda’s holistic initiatives in 2022, the Access to Medicines (ATM) Summit gathered 137 multi-sectoral stakeholders from 42 organizations for a 2-day meeting, and discussed how each can support healthcare strengthening in the Philippines. Takeda’s framework is to build sustainable capacity at every stage from diagnosis to ongoing patient support. To date, more than 1,700 pathologists, 6,997 oncology and 5,683 endoscopy nurses, 4 medical societies, and 7 NGOs and patient organizations have partnered with Takeda in these endeavors.

The second award recognized Takeda for its unwavering dedication to employee well-being and engagement in the Investment in People category. These programs aim to foster a healthy and collaborative working environment, enabling employees to thrive personally and professionally.

From L-R: Joanna Noor, Sheryll Corpuz, Dr. Felycette Gay Lapus, Dr. Arielle  Severino, and Caroline Ramira during the 2022 Philippine Society of Medical Oncology (PSMO) Annual Convention.

Takeda's employee well-being and engagement programs encompass diverse wellness initiatives and engagement activities that encourage a robust and motivated workforce. From the Partnerships for Growth (PFG) mentoring program, Lunch and Learn sessions, to career development and energy management workshops, Takeda invests in its employees' growth and development. These engagement efforts cultivate open communication, collaborative relationships, and contribute to the company's talent development and retention strategies, resulting in sustained high engagement levels with an average of 92% in the last two years of the company’s annual engagement survey.

Takeda's dedication to its employees has also led to the prestigious Great Place to Work® certification for two consecutive years, as well as one of 2023 Philippines Best Workplaces. The company remains steadfast in ensuring its programs cater to the needs of its workforce, empowering them to flourish and reach their full potential.

"We are honored to receive these recognitions as it cements Takeda’s enduring commitment to serve communities as well as our employees," Loreann Villanueva, Country Manager of Takeda Healthcare Philippines Inc. said. "These awards inspire us to push the boundaries further, making a lasting difference to the Filipino community through an empowered and highly dedicated workforce."

AREA recognizes and honors deserving Asian businesses for championing sustainable and responsible business practices in the following categories: Green Leadership, Social Empowerment, Health Promotion, Investment in People, Corporate Governance, Circular Economy Leadership, Corporate Sustainability Reporting and Responsible Business Leadership.

Takeda Healthcare Philippines Inc. is a wholly-owned subsidiary of Takeda Pharmaceutical Company Limited, a global R&D-driven biopharmaceutical company. Its headquarters in Makati City are home to Takeda Philippines’ employees who all share the same passion, drive, and commitment towards delivering life-transforming treatments, and sustainable patient access programs.

To learn more about Takeda and its initiatives, please visit www.takeda.com.

 

------------------------------------

About Takeda

Takeda is focused on creating better health for people and a brighter future for the world. We aim to discover and deliver life-transforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Together with our partners, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading values-based, R&D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people and the planet. Our employees in approximately 80 countries and regions are driven by our purpose and are grounded in the values that have defined us for more than two centuries.

Takeda Healthcare Philippines, Inc. (THPI) is a wholly-owned subsidiary of Takeda Pharmaceutical Company Limited. Founded in 1968, THPI aims to broaden patient access to treatment across the country through sustainable access programs enabling affordable and integrated access solutions for disease areas such as oncology, gastroenterology, rare diseases & vaccines and by strengthening the healthcare system guided by our commitment to Patients, our People and the Planet.

For more information, visit https://www.takeda.com.

 

Takeda partners with CARE PH to improve and expand cancer research

Tweet

Biopharmaceutical leader Takeda Healthcare Philippines Inc. has forged a partnership with Cancer Care Registry and Research Philippines Foundation (CARE PH) to expand cancer research efforts with the ambition to provide a comprehensive range of support for Filipino cancer patients.

(From left to right) Loreann Villanueva, Country Manager, Takeda Healthcare Philippines together with Igor Gomes, Takeda’s Cluster Head and General Manager for Vietnam, Malaysia, Philippines and Singapore (VMAPS) hands over Takeda’s grant to Dr. Beatrice Tiangco, Founder of CARE PH and Mr. Jojo Flores, Program and Administrative Officer of CARE PH

CARE PH is a non-government organization founded by Dr. Beatrice Tiangco in 2017 in response to the Department of Health’s (DOH) initiative on establishing a unified registry system in the country for non-communicable diseases such as cancer, stroke, diabetes, and heart disease. One of their main goals is to create and populate a hospital-based cancer registry to supplement existing population-based registries in Rizal and Metro Manila.

Through this partnership, Takeda will provide CARE PH a grant of Php 1,000,000 pesos with a goal of supporting the organization’s mission of “every preventable cancer averted, every screen-able cancer detected, and every cancer patient counted.” 

“This partnership with CARE PH ensures that we improve diagnostic rates for blood cancers such as myeloma, leukemia, and lymphoma, as well as other cancers, to increase the chances of prevention and cure in the Philippines. This will help Filipino cancer patients gain accelerated access to life-changing treatments,” shared Igor Gomes, Takeda’s Cluster Head and General Manager for Vietnam, Malaysia, Philippines and Singapore (VMAPS). 

Together for better oncology research and care 

According to DOH, non-communicable diseases are the top causes of death worldwide.  In the Philippines, cancer affects 189 out of every 100,000 Filipinos, with four Filipinos dying of cancer every hour or 96 cancer patients every day . As such, cancer ranks fourth (4th) as the leading cause of death in the Philippines with 48,937 recorded cases from January to October 2021 as stated by the Philippine Statistics Authority (PSA). 

Further, based on the research by the Global Cancer Observatory (Globocan), over 4,000 new patients were diagnosed with lymphoma, making it one of the top 30 cancers in the country. Approximately 300,000 deaths from this disease was recorded in 2020 alone, 2,500 of which occurred in the Philippines.

Representatives from Takeda Philippines and Care PH doing the symbolic gesture of Takeda’s Spot Lymphoma, Stop Lymphoma campaign. (From left to right) Loreann Villanueva, Country Manager, Takeda Philippines; Igor Gomes, Cluster Head and General Manager, VMAPS; Dr. Beatrice Tiangco, Founder of Care PH; and Mr. Jojo Flores, Program and Administrative Officer of Care PH

“We appreciate the liberty that Takeda has given to us in terms of how we can further improve our operations–from recruiting volunteers, hospitals, and towards initiating more cancer-related studies. Our main focus in this initiative are the Filipino cancer patients. We want to be able to provide them with registry and research outputs on the epidemiology of cancer in the country, which in turn will help prioritize screening, prevention and therapeutic initiatives, on the road to better healthcare for the Filipino cancer patient,” said Dr. Beatrice Tiangco, Medical Oncologist/Epidemiologist and Founder of CARE PH.

With a standardized and consolidated hospital registry, more robust data can be gathered, more scientific research using local data can be published, and constructing evidence-based clinical practice guidelines will be facilitated.

The Takeda grant will also allow CARE PH to donate computers to be able to train more data encoders at various hospitals throughout the country, and spearhead additional site-specific cancer registries and studies, maybe even contribute to the research and development of newer therapeutic agents for the nation’s common cancers.

“This partnership with CARE PH is something that we are very enthusiastic about since we share the same value and commitment towards bringing better health and brighter future to cancer patients,” shared Loreann Villanueva, Country Manager, Takeda Healthcare Philippines Inc.

-----------------------------------------------------

About Takeda

Takeda is a global, research and development-driven pharmaceutical company committed to bringing better health and a brighter future to patients by translating science into life-changing medicines. Takeda focuses its research efforts on four therapeutic areas - Oncology, Rare Diseases, Neuroscience and Gastroenterology - to develop highly innovative medicines that contribute to making a difference in people's lives.

About Takeda Philippines 

Takeda Healthcare Philippines, Inc. (THPI) is a wholly-owned subsidiary of Takeda Pharmaceutical Company Limited. Founded in 1968 and headquartered in Makati City, THPI aims to broaden patient access to treatment across the country through sustainable access programs enabling affordable and integrated access solutions for disease areas such as oncology, gastroenterology, rare diseases and by strengthening the healthcare system guided by our commitment to Patients, our People and the Planet.

Takeda Philippines recognized as Top Employer for the sixth consecutive year

Tweet

Biopharmaceutical leader Takeda Healthcare Philippines Inc. was re-certified as a Top Employer in the country for the sixth consecutive year by Top Employers Institute. This serves as an acknowledgement of Takeda’s excellence in people practices.

“I believe that one of the reasons why we continue to be recognized as a top employer is because we provide our employees a work setting where the job serves a deeper meaning and purpose,” shared Loreann Villanueva, Country Manager, Takeda Healthcare Philippines Inc. “We are driven by the possibility that what we do on a daily basis can make a difference not only in the lives of our stakeholders, but all the more in the lives of many Filipino patients.”

She added, “Our focus is on reaching out to patients who need our medicines through our Patient Access Program (PAP). This is a source of inspiration for our employees because we believe that the work that we do benefits hundreds of Filipino patients facing barriers to access life-transforming treatments.”

Takeda Healthcare Philippines also takes pride in its various Engagement Programs to ensure the holistic wellbeing of its employees. These efforts include monthly TGIF, sending of quarterly care packages, weekly prayer and exercise sessions, and even coffee catchups with the Country Manager. In addition, the company has talent development initiatives, which include Mentoring Program, Lunch and Learn sessions, online training programs, and internal and external workshops to keep its employees purposeful in their development, and resilient and agile especially during uncertain times.

Recently, Takeda also launched “Spot Lymphoma, Stop Lymphoma,” a campaign that aims to raise awareness about lymphoma and to improve access to lymphoma treatments in the Philippines by providing free testing to patients, partnering with relevant organizations and institutions, and sponsoring talks and seminars to educate the public about the disease. Lymphoma is the most common type of blood cancer in the world, and in the country, there were over 4,000 new patients that were diagnosed with this disease in 2020.

Takeda also bagged the Global Top Employer award for the fifth year in a row for its achievements in the areas of ethics and integrity, values, business strategy, organization and change, and employer branding across the globe. This makes them one of only 11 companies to achieve global Top Employer certification for 2022.

In addition, Takeda is also recognized as a Top Employer across four business regions and 39 countries and regions, reinforcing its steadfast commitment to create a diverse and inclusive organization that enables its people to thrive.

“This serves as a testament to Takeda’s long-standing values,” shared Villanueva. “It also recognizes our initiatives to support and develop talent in all levels of the organization.”

Takeda Healthcare Philippines is a wholly-owned subsidiary of Takeda Pharmaceutical Company Limited, a global R&D-driven biopharmaceutical company. Its headquarters in Makati City is home to its employees who all share the same passion, drive, and commitment towards delivering life-transforming treatments, sustainable patient access programs, and vaccines in the areas of oncology, gastroenterology, and rare diseases.

Established more than 30 years ago, Top Employers Institute is the global authority on recognizing excellence in people practices. Currently it has close to 2,000 organizations in 123 countries and regions.

For more information on Takeda, visit www.takeda.com.

About Takeda

Takeda is a global, research and development-driven pharmaceutical company committed to bringing better health and a brighter future to patients by translating science into life-changing medicines. Takeda focuses its research efforts on four therapeutic areas - Oncology, Rare Diseases, Neuroscience and Gastroenterology - to develop highly innovative medicines that contribute to making a difference in people's lives.

Takeda Healthcare Philippines, Inc. (THPI) is a wholly-owned subsidiary of Takeda Pharmaceutical Company Limited. Founded in 1968, THPI aims to broaden patient access to treatment across the country through sustainable access programs enabling affordable and integrated access solutions for disease areas such as oncology, gastroenterology, rare diseases & vaccines and by strengthening the healthcare system guided by our commitment to Patients, our People and the Planet.